ArticlePharmacopsychiatry2022
Classic Psychedelic Drugs: Update on Biological Mechanisms.
Article in Pharmacopsychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Drug-drug interactions involving classic psychedelics: A systematic review.Journal of psychopharmacology (Oxford, England) · 2024Pooled it
- Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results.Neuroscience and biobehavioral reviews · 2023Pooled it
- Psilocybin increases emotional empathy in patients with major depression.Molecular psychiatry · 2025Trial
- Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Trial
- Moving beyond 5-HTPsychopharmacology · 2026Article
- The Emergence of Isotryptamine Analogs as Novel Serotonergic Agents with Psychotherapeutic Potential.ACS pharmacology & translational science · 2026Review
- Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability.Molecular psychiatry · 2026Review
- Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA.Translational psychiatry · 2026Article
- Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations.Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2026Review
- Acute DOI exposure drives cortical hyperexcitability and functional network remodeling.bioRxiv : the preprint server for biology · 2026Article
- Facing trauma under the influence of psychedelics: A phenomenological study with Nova rave survivors.Journal of psychopharmacology (Oxford, England) · 2026Article
- Cannabis and Psychedelics Among U.S. Young Adults: Use, Messaging Exposure, Perceptions, and Legalization Support.International journal of environmental research and public health · 2026Article
- Sex-dependent effects of psychedelics: review of evidence from rodent models.Frontiers in psychiatry · 2026Review
- Psilocybin alters visual contextual computations.Nature communications · 2025Article
- Females in Psychedelic Research: A Perspective for Advancing Research and Practice.ACS pharmacology & translational science · 2025Review
- The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses.Translational psychiatry · 2025Article
- Network control energy reductions under DMT relate to serotonin receptors, signal diversity, and subjective experience.Communications biology · 2025Article
- Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning-Based Advanced Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications.Brain sciences · 2025Review
- The phenomenology of psilocybin: transformative insights for research and clinical practice.Frontiers in psychology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renewed interest in the effects of psychedelics in the treatment of psychiatric disorders warrants a better understanding of the neurobiological mechanisms underlying the effects of these substances. During the past two decades, state-of-the-art studies of animals and humans have yielded new important insights into the molecular, cellular, and systems-level actions of psychedelic drugs. These efforts have revealed that psychedelics affect primarily serotonergic receptor subtypes located in cortico-thalamic and cortico-cortical feedback circuits of information processing. Psychedelic drugs modulate excitatory-inhibitory balance in these circuits and can participate in neuroplasticity within brain structures critical for the integration of information relevant to sensation, cognition, emotions, and the narrative of self. Neuroimaging studies showed that characteristic dimensions of the psychedelic experience obtained through subjective questionnaires as well as alterations in self-referential processing and emotion regulation obtained through neuropsychological tasks are associated with distinct changes in brain activity and connectivity patterns at multiple-system levels. These recent results suggest that changes in self-experience, emotional processing, and social cognition may contribute to the potential therapeutic effects of psychedelics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.